Application No. 09/786,435
Filed: March 20, 2001
TC Art Unit: 1645
Confirmation No.: 1324

AMENDMENT TO THE CLAIMS

1. (Currently Amended) A method for inhibiting the biological activity of transforming growth factor β on predamaged neurons in cerebral disorders, said method comprising the steps of:

providing a patient having predamaged neurons; and

treating said predamaged neurons in said patient with a compound ~~inhibiting~~ that inhibits the biological activity of TGF-β on said predamaged neurons.

2. - 4. (Cancelled)

5. (Currently Amended) A pharmaceutical composition ~~containing~~comprising, in pharmaceutically effective amounts, a first compound capable of substantially inhibiting the biological activity of TGF-β on predamaged neurons caused by cerebral disorders, and a second compound for disintegrating blood clots, wherein said first and second compounds are formulated in~~and optionally~~ a pharmaceutically acceptable carrier ~~and/or diluent~~.

6. (Original) The pharmaceutical composition according to claim 5, wherein said compound is an antibody directed to TGF-β or a compound having the binding site of a TGF-β receptor.

7. (Original) The pharmaceutical composition according to claim 5, wherein said compound is an antibody directed to TGF-β or a compound having the binding site of a TGF-β receptor.

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
TEL. (617) 542-2290
FAX. (617) 451-0313

Application No. 09/786,435
Filed: March 20, 2001
TC Art Unit: 1645
Confirmation No.: 1324

8. (Original) The pharmaceutical composition according to claim 5, wherein said second compound is selected from the group consisting of urokinase and tissue plasminogen activator.

9. - 10. (Cancelled)

11. (Previously Presented) The pharmaceutical composition according to claim 6, wherein said compound is an antibody directed to TGF-β or a compound having the binding site of a TGF-β receptor.

12. (Previously Presented) The pharmaceutical composition according to claim 6, wherein said second compound is selected from the group consisting of urokinase and tissue plasminogen activator.

13. (Previously Presented) The pharmaceutical composition according to claim 12, wherein said second compound is selected from the group consisting of urokinase and tissue plasminogen activator.

14. (Previously Presented) The method of claim 1, wherein said compound inhibiting the biological activity of TGF-β is selected from the group consisting of (1) an antibody to TGF-β, (2) an antagonist to TGF-β, and (3) a compound capable of altering TGF-β.

15. (Previously Presented) The method of claim 14 wherein said compound is selected from the group consisting of TGFG-β

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
TEL. (617) 542-2290
FAX. (617) 451-0313

Application No. 09/786,435
Filed: March 20, 2001
TC Art Unit: 1645
Confirmation No.: 1324

inhibitors, compounds having the binding site of a TGF-β receptor, and TGF-β RII/Fc chimeric protein.

16. (Currently Amended) The method of claim [[14]]1, wherein said method further comprises treating said patient with ~~treatment also includes~~ a second compound for disintegrating blood clots.

17. (Previously Presented) The method of claim 16 wherein said second compound is selected from the group consisting of urokinase, thrombin and tissue plasminogen activator.

18. (Currently Amended) The method of claim [[14]]1, wherein said compound is administered intravenously, orally or intracerebrally.

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
TEL. (617) 542-2290